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Abstract
Background: Mesenchymal stromal cells (MSCs) are investigated for their potential to reduce inflammation and to
repair damaged tissue. Inflammation and tissue damage are hallmarks of chronic obstructive pulmonary disease
(COPD) and MSC infusion is a promising new treatment for COPD. Inflammatory mediators attract MSCs to sites of
inflammation and affect their immune-modulatory properties, but little is known about their effect on regenerative
properties of MSCs. This study investigates the effect of the pro-inflammatory cytokines TNF-α and IL-1β on the
regenerative potential of MSCs, using an in vitro wound healing model of airway epithelial cells.
Methods: Standardized circular wounds were created by scraping cultures of the airway epithelial cell line NCI-
H292 and primary bronchial epithelial cells cultured at the air-liquid interface (ALI-PBEC), and subsequently
incubated with MSC conditioned medium (MSC-CM) that was generated in presence or absence of TNF-α/IL-1β.
Remaining wound size was measured up to 72 h. Phosphorylation of ERK1/2 by MSC-CM was assessed using
Western blot. Inhibitors for EGFR and c-Met signaling were used to investigate the contribution of these receptors
to wound closure and to ERK1/2 phosphorylation. Transactivation of EGFR by MSC-CM was investigated using a
TACE inhibitor, and RT-PCR was used to quantify mRNA expression of several growth factors in MSCs and NCI-H292.
Results: Stimulation of MSCs with the pro-inflammatory cytokines TNF-α and IL-1β increased the mRNA expression
of various growth factors by MCSs and enhanced the regenerative potential of MSCs in an in vitro model of airway
epithelial injury using NCI-H292 airway epithelial cells. Conditioned medium from cytokine stimulated MSCs
induced ERK1/2 phosphorylation in NCI-H292, predominantly via EGFR; it induced ADAM-mediated transactivation
of EGFR, and it induced airway epithelial expression of several EGFR ligands. The contribution of activation of c-Met
via HGF to increased repair could not be confirmed by inhibitor experiments.
Conclusion: Our data imply that at sites of tissue damage, when inflammatory mediators are present, for example
in lungs of COPD patients, MSCs become more potent inducers of repair, in addition to their well-known immune-
modulatory properties.
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Background
In chronic obstructive pulmonary disease (COPD), the
release of proteases and other mediators by a variety of
inflammatory and resident cells is thought to cause tis-
sue damage within the lung [1–3]. The endogenous re-
generative capacity of the lung to restore damaged
structures is limited, and the resulting imbalance be-
tween insufficient repair mechanisms and excess tissue
damage will lead to irreversible tissue damage [4], ultim-
ately causing organ failure.
Current COPD treatment targets symptoms, and there
is a lack of treatments that halt disease progression and/
or restore lung structure. The only current option for
patients with chronic respiratory failure due to severe
emphysema is lung transplantation, but the availability
of donor lungs is limited and the success of lung trans-
plantation varies. Therefore, new approaches to restore
damaged lung tissue in COPD are needed.
A promising therapeutic approach that targets restor-
ation of destructed lung tissue as well as reduction of
inflammation is the administration of mesenchymal stro-
mal cells (MSCs). MSCs are multipotent progenitor cells
of non-hematopoietic origin defined by their capacity to
differentiate into multiple lineages of the mesenchyme
[5]. Besides their differentiation capacity, MSCs can
favour repair of wounded tissue by modulating cellular
responses in structural and immune cells, creating a re-
generative and anti-inflammatory environment (reviewed
in [6, 7]). The main mechanisms by which MSCs exert
these effects are via cell-cell interactions and secretion
of soluble factors.
Indeed, MSCs can reduce inflammation and repair al-
veolar structures as has been demonstrated in in vivo ro-
dent models of cigarette smoke or elastase-induced
emphysema [8–10]. It has been suggested that MSCs
mediate this effect in part via the release of soluble fac-
tors, including hepatocyte growth factor (HGF) and epi-
dermal growth factor receptor (EGFR) ligands, which
can both increase proliferation of epithelial cells [11–15].
The receptors for these growth factors, c-Met and EGFR
respectively, can activate extracellular signal-regulated
kinase 1/2 (ERK1/2), one of the mitogen activated protein
kinases (MAPK). Activation of this signaling pathway
results in proliferation, differentiation and migration,
processes that are fundamental for wound repair [16].
Whereas conditioned medium from MSCs has been
shown to enhance airway epithelial wound healing in vitro
[17], the contribution of HGF or EGFR ligands and under-
lying ERK1/2 signaling has not yet been investigated.
Another interesting and yet unanswered issue is whether
pro-inflammatory cytokines can affect the potential of
bone-marrow derived MSCs to repair damaged pulmonary
epithelium at sites of inflammation. It is known that
inflammatory mediators can attract MSCs (reviewed
in [18, 19]) and alter their secretome [20–24], which
is beneficial for the immune response [22] and for
skin wound healing [25]. However, whether inflammatory
mediators also increase the potential of bone marrow-
derived MSCs to repair damaged pulmonary epithelium
remains to be elucidated. Moreover, the cellular and
molecular mechanisms that underlie such a repair po-
tentiating effect within the airway epithelium are largely
unknown.
Therefore, in the present study we investigated the
effect of pro-inflammatory cytokines involved in the
pathogenesis of COPD (i.e. Tumour Necrosis Factor-α
(TNF-α) and Interleukin-1β (IL-1β)) [26–29] on the ex-
pression of growth factors by MSCs. We explored the ef-
fect of the conditioned medium from these stimulated
MSCs on airway epithelial wound repair in vitro, and the
contribution of the ERK1/2 signaling pathway, c-Met
and EGFR to this effect. Our results show that stimulation
of MSCs with TNF-α and IL-1β increases their regenera-
tive potential as assessed in an in vitro model of airway
epithelial repair. Furthermore, we demonstrate the crucial
involvement of EGFR-activation in this process.
Methods
Cell culture
Cells from the NCI-H292 human lung mucoepidermoid
carcinoma epithelial cell line (American Type Culture
Collection, Manassas, VA, USA) were cultured in RPMI
1640 (Gibco, Grand Island, NY, USA), supplemented with
100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM
glutamine (all from Bio Whittaker, Walkersville, MD,
USA) and 10 % [v/v] heat inactivated fetal calf serum
(FCS) (Bodinco, Alkmaar, The Netherlands). Human pri-
mary bronchial epithelial cells (PBEC) isolated from
tumour-free bronchial tissue [30] were cultured on semi-
permeable transwell membranes with a 0.4 μm pore size
(Corning Costar, Cambridge, MA, USA). Transwells were
coated with 30 μg/ml PureCol (Advanced BioMatrix, San
Diego, CA, USA), 10 μg/ml bovine serum albumin (BSA)
(Sigma-Aldrich, St. Louis, MO, USA) and 10 μg/ml fibro-
nectin diluted in PBS. Upon establishment of a confluent
cell layer, PBEC were cultured at the air-liquid interface
(ALI) during 2 weeks for differentiation. Culture medium
consisted of a 1:1 mixture of bronchial epithelial growth
medium (BEGM) (Lonza, Verviers, Belgium) and Dulbec-
co’s modified Eagle’s medium (DMEM) (Gibco), supple-
mented with 0.4 % (w/v) bovine pituitary extract (BPE),
1 μM hydrocortisone (HC), 0.5 ng/ml human epidermal
growth factor (hEGF), 0.5 μg/ml epinephrine, 10 μ/ml
transferrin, 5 μg/ml insulin, T3, 0.1 ng/ml retinoic acid
(RA), 1 mM Hepes (all Lonza), 1 mg/ml BSA (Sigma-
Aldrich), 100 U/ml penicillin and 100 μg/ml streptomycin
(Lonza), and additional supplementation of 15 ng/ml RA
(Sigma-Aldrich) for mucociliary differentiation.
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Mesenchymal stromal cells (MSCs) were isolated from
bone marrow from healthy donors and expanded in
culture following a previously described protocol of the
department of Immunohaematology and Blood Transfu-
sion at Leiden University Medical Center [31]. MSC
characterization was based on morphology and immu-
nophenotyping using flow cytometry for the following
markers: HLA-DR, CD73, CD90, CD31, CD34, CD45,
CD80 (Becton Dickinson (BD) Bioscience, Franklin Lakes,
NJ, USA) and CD105 (Ancell, Bayport, MN, USA), using
FACSCalibur and CellQuest Pro Software (BD Bio-
science). MSCs were cultured in DMEM GlutaMAX™
(Gibco), supplemented with 100 U/ml penicillin and
100 μg/ml streptomycin, and 10 % [v/v] heat-inactivated
FCS (Thermo Fisher Scientific, UT, USA). All cells were
cultured at 37 °C in a 5 % CO2 humidified incubator. Be-
fore experiments, NCI-H292 and MSCs were starved for
growth factors overnight using serum-free (SF) culture
medium; ALI-PBEC were starved for growth factors in B/
D medium lacking BPE, HC, hEGF, RA and BSA. Prior to
experiments, the apical side of ALI-PBEC cultures was
washed with 100 μL of PBS to remove excess mucus.
Preparation of conditioned medium
MSCs were grown until 80–90 % confluence and starved
overnight in serum-free medium after washing with PBS.
To generate MSC conditioned medium (MSC-CM), cells
were cultured for 24 h in either serum-free medium
(LG-DMEM) containing TNF-α and IL-1β (both 20 ng/
ml; Peprotech, Rocky Hill, NJ, USA) (to generate MSC-
CMSTIM) or serum-free medium alone (to generate
MSC-CMCTRL). MSC-CM from different donors and
generated at different passages was pooled before experi-
ments to reduce effects caused by donor and/or passage
variation. All wound healing experiments were per-
formed with MSC-CM at passage 4–6. A part of the
western blot experiments were performed with MSC-
CM at passage 2–4. Control DMEM medium with TNF-
α and IL-1β (DMEMSTIM) or without (DMEMCTRL) was
obtained by incubating medium in culture flasks not
containing cells in the same incubator for 24 h. MSC-
CM and DMEM control medium were harvested and
centrifuged for 7 min at 230xg to remove debris, and
stored in 2 ml aliquots at -80 °C until further use.
Wound repair model
A confluent monolayer of NCI-H292 cells or differenti-
ated ALI-PBEC was mechanically injured by scraping
the cell layer with a sterile Pasteur pipette with a soft tip
(essentially as described in [32]). Two wounds with a
diameter of 3 mm each were made in each well in a 12
wells plate for NCI-H292, or one wound per Transwelll
insert for ALI-PBEC. Each experiment was performed in
duplicate. After wounding, medium was replaced by the
following stimuli: serum free standard culture medium
(negative control); 20 ng/ml Transforming Growth
Factor-α (TGF-α) (Sigma-Aldrich, St. Louis, MO, USA)
in serum free standard culture medium (positive control
[32]); or MSC-CM and the corresponding DMEM con-
trols, which were all diluted 1:2 in serum free standard
culture medium (based on dose response experiments),
unless otherwise specified. For inhibitor experiments ex-
ploring the role of c-Met and the Epidermal Growth
Factor receptor (EGFR) in wound healing, 0.05 μM
PF04217903 (c-Met inhibitor; Sigma-Aldrich) and/or
0.2 μM AG1478 (EGFR tyrosine kinase inhibitor; Calbio-
chem, Darmstadt, Germany) were added to relevant
stimuli for the full culturing period. Hepatocyte Growth
Factor (HGF) (Peprotech) and TGF-α (both at 20 ng/ml
in LG-DMEM) served as positive controls, whereas LG-
DMEM was used as negative control (DMEMCTRL).
Digital images of the wounds were collected every
24 h up to 72 h maximum (NCI-H292) or at 6, 24 and
48 h (ALI-PBEC), on an inverted phase-contrast light
microscope using Cell Sense Entry imaging software
(both from Olympus, Tokyo, Japan). The surface of the
wound area was measured using Image J software
(National Institutes of Health, USA), and residual wound
area in percentage was assessed by comparing the
remaining wound size at different time points with the
wound size at the start of the experiment ((1-wound size
t = x/wound size t = 0)*100).
Phosphorylation of ERK1/2
NCI-H292 cells used for assessment of ERK1/2 phosphor-
ylation were cultured to 70 % confluence in a 12 wells
plate. All stimuli were diluted 1:2 in RPMI. Cells were
stimulated with either MSC-CMSTIM or DMEMSTIM.
HGF or TGF-α in a final concentration of 20 ng/ml di-
luted in LG-DMEM and DMEMCTRL were used as posi-
tive resp. negative controls.
The role of c-Met and EGFR activation was investi-
gated by pre-incubation of cells during 1 h with either
0.05 μM PF04217903, or 10 μM AG1478, or 2 μg/ml
neutralizing antibodies against EGFR (Calbiochem) dis-
solved in RPMI in assigned wells before addition of
stimuli. The role of transactivation was evaluated using
the TNF-α converting enzyme (TACE)/ADAM17 inhibi-
tor TAPI-1 (10 μM) (Santa Cruz Biotechnology, Dallas,
TX, USA). Controls were treated with an equal volume
of RPMI for 1 h.
Cells were incubated with stimuli for 15 min or vari-
ous time periods for time-series experiments, and imme-
diately cooled down on ice and washed with cold ERK
washing buffer (5 mM Tris pH 7.4, 100 mM NaCl,
1 mM CaCl2, 1 mM MgCl2). Cell lysates were generated
by incubation with lysis buffer (0.5 % [v/v] Triton X-100,
1 mM Na3VO4 and Mini complete protease cocktail
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(Roche, Basel, Switzerland) in ERK washing buffer) for
15 min. Samples from duplicate wells were pooled. After
dilution in 2 times concentrated reducing sample buffer
(4 % [v/v] SDS, 10 % [v/v] beta-Mercaptoethanol, 20 % [v/
v] glycerol, 0.5 M Tris pH 6.8 and 0.003 % [w/v] Bromphe-
nol blue) samples were boiled for 5 min and spun down at
20780xG for 5 min, before loading and running on a 10 %
SDS-PAGE gel. Proteins were transferred onto a polyviny-
lidene difluoride membrane using the Mini-transblot sys-
tem (both from Bio-Rad, Hercules, CA, USA).
Non-specific binding sites on the blots were blocked
with PBS/0.05 % [v/v] Tween 20/0.5 % [w/v] casein
(Sigma-Aldrich) for at least one hour followed by over-
night incubation at 4 °C with antibodies directed against
total and phospho-ERK1/2 (Cell Signaling, Beverly, MA,
USA) in PBS/0.05 % Tween 20. After washing of the blot
with PBS/0.05 % Tween 20, secondary HRP labeled goat
antibodies (BD Bioscience) were added for 1 h at room
temperature, followed by extensive washing. The mem-
branes were developed on film (FujiFilm Corporation,
Tokyo, Japan) using enhanced chemiluminescent (ECL)
detection system (ThermoScientific, Rockford, IL, USA).
mRNA expression
NCI-H292 cells were grown to near confluence and ex-
posed to MSC-CMSTIM or DMEMSTIM or DMEMCTRL
(neg ctrl) 1:2 in RPMI. MSCs were grown to 80–90 % con-
fluence and stimulated with TNF-α and IL-1β (20 ng/ml
each) or serum free medium. Incubation times were based
on initial experiments on limited samples revealing the
largest increase of mRNA expression for several genes
after 9 h (NCI-H292) and 6 h (MSCs) of stimulation. Sam-
ple triplicates from a 24 wells plate were pooled and RNA
was extracted using Maxwell® 16 RNA Purification Kit
(Promega, Madison, WI, USA) according to the man-
ufacturers protocol, and quantified using the Nano-
drop ND-1000 UV-visible spectrophotometer (Nanodrop
Technologies, Wilmington, DE, USA). Complementary
DNA was generated by adding Oligo(dT) primers (Qia-
gen, Düsseldorf, Germany) and 10 nM dNTP mix (Pro-
mega) to the RNA sample, and heating this to 65 °C for
5 min. Subsequently, 5x 1st strand RNA buffer, RNasin
and M-MLV (all from Promega) were added, and the sam-
ples were incubated at 37 °C during 50 min followed by
heat inactivation of M-MLV at 70 °C during 15 min.
Primers were designed using PubMed Gene Database
and Primerbank (http://pga.mgh.harvard.edu/primerbank)
(Table 1) (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA). Quantitative real-time PCR was performed in
triplicate in a 384 wells plate (Bio-Rad CFX384™), with
samples mixed with respective primers and SYBR Green
supermix (Bio-Rad) in a final volume of 8 μl. Results were
checked for outliers: outliers were removed if the variance
within triplicates was above 10 %.
Expression of ACTB and GAPDH was used to nor-
malize mRNA expression in MSCs, whereas RPL13A
and ATP5B were used for NCI-H292 (Table 1).
Statistics
The data are expressed as mean ± standard error of the
mean unless depicted otherwise. GraphPad Prism 6.0
(GraphPad Inc., La Jolla, CA, USA) was used for statis-
tical analysis. For comparison between groups, the
Mann-Whitney test was used, for comparison of three
or more groups the Kruskall Wallis test. Differences
were considered significant when p < 0.05.
Table 1 Primers for RT-PCR
GENE Primer sequence FW Primer sequence RV
ACTB TTC CAG GAG CGA GAT CCC T CAC CCA TGA CGA ACA TGG G
ATP5B TCA CCC AGG CTG GTT CAG A AGT GGC CAG GGT AGG CTG AT
GAPDH TTC CAG GAG CGA GAT CCC T CAC CCA TGA CGA ACA TGG G
RPL13A AAG GTG GTG GTC GTA CGC TGT G CGG GAA GGG TTG GTG TTC ATC C
AREG GGT GGT GCT GTC GCT CTT G AGG TGT CAT TGA GGT CCA ATC C
CCDN1 CAA TGA CCC CGC ACG ATT TC CAT GGA GGG CGG ATT GGA A
EGF TGC AGA GGG ATA CGC CCT AA CAA GAG TAC AGC CAT GAT TCC AAA
FGF2 TGG CTA TGA AGG AAG ATG GAA GA TCC AAT CGT TCA AAA AAG AAA CAC
HB-EGF TGG ACC TTT TGA GAG TCA CTT TAT CC CGT GCT CCT CCT TGT TTG GT
HGF TCC AGA GGT ACG CTA CGA AGT CT CCC ATT GCA GGT CAT GCA T
IL6 CAG AGC TGT GCA GAT GAG TAC A GAT GAG TTG TCA TGT CCT GCA G
PDGFA CAC CAC CGC AGC GTC AA CCT CAC CTG GAC TTC TTT TAA TTT TG
TGFA AGG TCC GAA AAC ACT GTG AGT AGC AAG CGG TTC TTC CCT TC
VEGF CGA GGG CCT GGA GTG TGT TGG TGA GGT TTG ATC CGC ATA
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Results
Stimulation of MSCs with pro-inflammatory cytokines
induces mRNA expression of several growth factors and
leads to increased protein levels of HGF
To investigate the effect of pro-inflammatory cytokines on
growth factor expression in MSCs, the mRNA expression
of a variety of growth factors was analyzed in MSCs stim-
ulated with TNF-α and IL-1β (20 ng/ml each).
The mRNA expression of the growth factors Fibroblast
Growth Factor 2 (FGF2), Hepatocyte Growth Factor
(HGF), Heparin-binding EGF-like growth factor (HBEGF)
and Interleukin-6 (IL6) was significantly increased (p <
0.05), and a non-significant increase was observed in
amphiregulin (AREG) (p = 0.06). mRNA expression of the
other growth factors evaluated did not change significantly
(Fig. 1).
MSC conditioned medium increases wound closure in
NCI-H292 monolayers
Exposure of MSCs to the pro-inflammatory cytokines
TNF-α and IL-1β resulted in increased mRNA expression
of several growth factors. To assess whether this observa-
tion has functional relevance, a wound closure model was
used to investigate the effect of MSC-CMSTIM on wound
closure in NCI-H292 airway epithelial cell monolayers.
No significant differences were observed when wounded
NCI-H292 cells were incubated with conditioned medium
from unstimulated MSCs (MSC-CMCTRL), compared to
the control medium (DMEMCTRL) (Fig. 2a). In contrast,
MSC-CM from TNF-α and IL-1β stimulated MSCs
(MSC-CMSTIM) significantly enhanced wound closure
compared to DMEMSTIM (also containing TNF-α and IL-
1β) after 24 and 48 h and was even more effective than
the positive control TGF-α (Fig. 2b, c) (p = 0.002 at 48 h).
The effect of MSC-CMSTIM was dose-dependent and still
detectable at a 1:10 dilution (Fig. 2d).
Next the effect of MSC-CM on wound closure in well-
differentiated cultures of ALI-PBEC was investigated.
Wound closure in ALI-PBEC cultures was faster than in
NCI-H292, and full wound closure was observed within
48 h. In ALI-PBEC, MSC-CMSTIM also significantly in-
creased epithelial wound closure, however to a similar
extent as its control (DMEMSTIM) (Fig. 2e, f ).
MSC-CMSTIM activates ERK1/2 signaling in NCI-H292
monolayers via (trans)activation of the EGF-receptor
The observation that MSC-CMSTIM enhanced wound
closure in NCI-H292 monolayers prompted further in-
vestigation into the underlying cellular response ac-
countable for this effect. Epithelial wound healing is
regulated by activation of mitogen activated protein ki-
nases (MAPKs), and in particular via activation of the
MAPK Extracellular signal-Regulated Kinase (ERK)1/2,
which is known to be involved in cell proliferation, dif-
ferentiation and migration [16, 33]. Therefore we further
examined the role of this pathway in MSC-CM induced
wound healing.
In NCI-H292 monolayers, MSC-CMSTIM increased
ERK1/2 phosphorylation, when compared to DMEMSTIM
(Fig. 3a, b). This effect was more pronounced at early time
points (15–30 min), but could be observed up to 6 h of
stimulation (Fig. 3c, d).
Fig. 1 Stimulation of MSCs with TNF-α and IL-1β increases the expression of several growth factors. MSCs were stimulated with TNF-α and IL-1β
20 ng/ml each and harvested for RNA extraction after 6 h. mRNA expression of various growth factors (AREG, EGF, HBEGF (all EGFR ligands), FGF2,
HGF, IL6, PDGFA, and VEGF) was determined by qPCR, which showed a significant increase of FGF2, HBEGF, HGF and of IL6, and an increase of AREG
and EGF. Values were normalized to ACTB and GAPDH reference genes. Box and whiskers represent median, interquartile range and minimum and
maximum for n = 4 obtained from three different donors; (*) p < 0.05
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Next, the involvement of two upstream receptors, c-Met
(HGF-receptor) and Epidermal Growth Factor Receptor
(EGFR), in ERK1/2 phosphorylation by MSC-CMSTIM was
explored using a tyrosine kinase inhibitor to block c-Met
and EGFR, or neutralizing anti-EGFR antibodies. Control
experiments showed that ligands for both c-Met (HGF)
and EGFR (TGF-α) are potent activators of ERK1/2, and
that the respective inhibitors block this activation effect-
ively and specifically (data not shown). At 15 min, phos-
phorylation of ERK1/2 by MSC-CMSTIM was inhibited by
the EGFR inhibitor (AG) and EGFR neutralizing anti-
bodies (αEGFR) (Fig. 4a-d), but was not affected by the c-
Met inhibitor (PF) (Fig. 4a, b). This shows that although
both EGFR and c-Met are potent activators of ERK1/2,
the increase in ERK1/2 phosphorylation as observed upon
stimulation with MSC-CMSTIM is mainly mediated via the
EGFR pathway.
Besides direct EGFR-dependent activation of ERK1/2 by
constituents of the MSC-CM, it is also known that airway
epithelial cells promote wound healing in an autocrine
manner, via transactivation of EGFR. In this process,
matrix metalloproteinases, predominantly TACE/ADAM17,
mediate the shedding of cell surface-bound EGFR ligands
[34]. These ligands in turn activate ERK1/2 via EGFR.
Addition of a TACE/ADAM17 inhibitor (TAPI-1) de-
creased ERK1/2 phosphorylation induced by MSC-CMSTIM
(Fig. 4c, d). This suggests that EGFR transactivation
through TACE/ADAM17 contributes to ERK1/2 phos-
phorylation in NCI-H292 monolayers, in addition to dir-
ect effects of MSC-CMSTIM.
Fig. 2 MSC-CM increases wound closure. a, b: NCI-H292 cells were injured by making a circular wound with a diameter of 3 mm, and subsequently
incubated with MSC-CMCTRL, MSC-CMSTIM, DMEMCTRL and DMEMSTIM, and a negative control (NC, RPMI only) and positive control (RPMI supplemented
with TGF-α 20 ng/ml). The wound size was measured at 0, 24, 48 and 72 h after wounding. MSC-CMSTIM significantly increased wound closure. The
effect of MSC-CMSTIM was dose-dependent. Error bars represent standard error of the mean (SEM). n = 4-6; (*) p < 0.05 TGF-α compared to NC and (**)
compared to DMEM; (***) p < 0.05 MSC-CM compared to NC and (****) compared to DMEM; (*****) p < 0.05 DMEMSTIM compared to NC. c: Morphology
of the closure of the wound: photos in the upper panel are taken at t = 0 h, the lower panel shows the same wounds photographed 48 h later. The
two photos on the left side are obtained from MSC-CMSTIM stimulated cells, whereas photos at the right represent its control, DMEMSTIM. d: Dose
response. Box and whiskers represent median, interquartile range and minimum and maximum. n= 4-6; (*) p < 0.05. e: Wound closure in ALI-PBEC
measured at 6 and 24 h (at 48 h all wounds were closed). At 24 h, MSC-CMSTIM significantly enhanced wound healing compared to the NC, but no
significant differences were observed compared to its control, DMEMSTIM. Error bars represent SEM, n = 4; (*) p < 0.05 for MSC-CMSTIM compared to NC.
f. Wound closure in ALI-PBEC at 24 h. Box and whiskers represent median, interquartile range and minimum and maximum, for n = 4 as in Fig. 2f;
(*) p < 0.05
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This raised the question whether MSC-CMSTIM could
induce EGFR ligand expression in airway epithelial cells.
To investigate this, NCI-H292 were incubated with MSC-
CMSTIM and gene expression of several EGFR ligands was
assessed. A significant increase of mRNA expression of
both AREG and HBEGF was observed upon stimulation
with MSC-CMSTIM compared to its control (Fig. 4e).
Enhanced ERK1/2 activation promotes in part cell pro-
liferation by increasing expression of Cyclin D1 (CCDN1)
[35], a cell cycle regulator. In line with MSC-CMSTIM in-
duced ERK1/2 phosphorylation, the mRNA expression of
CCDN1 was significantly higher compared to its control,
suggesting an increase in cell proliferation (Fig. 4f).
Blocking of the EGFR reduces the stimulatory effect of
MSC-CMSTIM on wound healing
In NCI-H292 monolayers, stimulation with MSC-CMSTIM
resulted in increased ERK1/2 phosphorylation, and this
process appeared to be predominantly regulated via EGFR
signaling. To assess if this observation could be translated
into a functional effect, wound healing experiments were
repeated using the before mentioned tyrosine kinase in-
hibitors. To limit toxic side effects after prolonged expos-
ure to high doses of AG, we adjusted the concentration of
AG to 0.2 μM based on dose-response experiments; for
the c-Met inhibitor PF a concentration of 0.05 μM sufficed
(data not shown).
The EGFR ligand TGF-α and the c-Met ligand HGF
both significantly enhanced wound healing in NCI-H292
monolayers, indicating that both their corresponding re-
ceptors could be involved in MSC-mediated wound re-
pair. Inhibition of EGFR as well as of c-Met blocked the
effect of TGF-α and HGF, respectively (Fig. 5a). In the
presence of the EGFR inhibitor the effect of MSC-
CMSTIM on wound closure was significantly reduced to
a level similar to that observed in the negative control.
Blocking of the HGF receptor c-Met alone had no effect
on wound closure induced by MSC-CMSTIM (Fig. 5b).
These data indicate that signaling through EGFR is the
predominant pathway by which MSC-CMSTIM increased
wound healing in NCI-H292 epithelial cells.
Discussion
This study shows for the first time that stimulation of
MSCs with pro-inflammatory cytokines improves their
capacity to enhance airway epithelial repair in an in vitro
repair model using the airway epithelial cell line NCI-
H292. We show that conditioned medium from human
bone marrow-derived MSCs increases wound healing in
airway epithelial cells and that this effect is significantly
enhanced when the MSCs are treated with a mixture of
pro-inflammatory cytokines, i.e. TNF-α and IL-1β. These
cytokines increased the mRNA expression of the growth
factors FGF2, HBEGF, HGF, and of IL6 in MSCs. We
provide evidence for the possible involvement of the
following mechanisms in this enhancing effect of MSC-
CMSTIM on wound repair (Fig. 6): first, MSC-CMSTIM
directly activated the MAP kinase ERK1/2 via EGFR,
Fig. 3 MSC-CMSTIM increases ERK1/2 phosphorylation. NCI-H292 cells were incubated with MSC-CMSTIM, DMEMSTIM, DMEMCTRL or TGF-α 20 ng/ml
(pos ctrl). ERK1/2 phosphorylation and total ERK was determined in cell lysates using Western blot. a: After 15 min incubation time MSC-CMSTIM
increased ERK1/2 phosphorylation compared to its control. b: Densitometry for Fig. 3a. Error bars represent SEM, n = 6; (*) p < 0.05. c: Time course
experiment, demonstrating that the effect of MSC-CMSTIM was most prominent up to 30 min, but could still be observed up to 6 h. DMEMCTRL
was obtained at 15 min. d: Densitometry for Fig. 3c. Error bars represent SEM, n = 4-5; (*) p < 0.05
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resulting in wound healing. Second, MSC-CMSTIM caused
ADAM-mediated transactivation of EGFR, further con-
tributing to wound healing. Third, MSC-CMSTIM in-
creased mRNA expression of EGFR ligands AREG and
HBEGF in NCI-H292 airway epithelial cells.
Previous studies show that MSCs contribute to epithe-
lial repair in wound healing models in vivo as well as in
vitro [8, 17, 36], and that pro-inflammatory cytokines
can attract MSCs to sites of inflammation [37]. Within
such an inflammatory environment, MSCs display an
anti-inflammatory phenotype that is characterized by an
increased expression of IL6 [38]. In line with this obser-
vation, we noted increased expression of IL6 in MSCs
stimulated with TNF-α and IL-1β, suggesting anticipated
response to these pro-inflammatory stimuli. Besides in-
creased mRNA expression of IL6, we observed increased
mRNA expression of several growth factors in TNF-α/
IL-1β stimulated MSCs, suggesting that the regenerative
potential of these MSCs is enhanced. The increased
mRNA expression of several EGFR ligands was not
accompanied by increased levels of these ligands as de-
tected by ELISA (data not shown). This may be ex-
plained by limitations in the sensitivity of the ELISAs,
rapid binding of secreted growth factors to their cellular
receptors, and/or by the fact that the observed effects
are not explained by detectable levels of single EGFR li-
gands, but by synergisms between various released media-
tors. In line with our observations, previous reports also
demonstrated that stimulation with pro-inflammatory
cytokines induces growth factor expression by MSCs
[20, 39, 40]. However, to our knowledge this is the first
study demonstrating that pro-inflammatory cytokine
Fig. 4 MSC-CMSTIM induced ERK1/2 phosphorylation is mediated via (trans)activation of EGFR. a: 1 h pre-incubation of NCI-H292 with 0.05 μM
PF04217903 and/or 10 μM AG1478, followed by 15 min stimulation with MSC-CMSTIM or DMEMSTIM, or DMEMCTRL showed that inhibition of EGFR
decreased ERK1/2 phosphorylation as determined using Western blot. b: Densitometry for Fig. 4a. Error bars represent SEM, n = 5; (*) p < 0.05.
c: 1 h pre-incubation with 2 μg/ml neutralizing anti-EGFR antibodies and 10 μM TAPI-1 followed by incubation with MSC-CMSTIM during 15 min
showed that these agents decreased ERK1/2 phosphorylation. d: Densitometry for Fig. 4c. Error bars represent SEM, n = 3; (*) p < 0.05. e: NCI-H292
cells were incubated with MSC-CMSTIM or DMEMSTIM and harvested after 9 h for mRNA analysis. mRNA expression of the EGFR ligands AREG,
HBEGF and TGFA was determined by qPCR. MSC-CMSTIM significantly increased the expression of AREG and HBEGF. Expression of TGFA increased
but this was not significant. f: mRNA expression of the proliferation marker CCDN1 was significantly increased. Values were normalized against
RPL13A and ATP5B reference genes. Box and whiskers represent median, interquartile range and minimum and maximum. n = 4; (*) p < 0.05
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stimulation of MSCs induces wound healing in airway epi-
thelial cells, and our data indicate that this may involve
the action of growth factors. Together, this suggests that
the capacity of MSCs to enhance wound repair may be in-
creased upon recruitment to areas of inflammation where
they are exposed to pro-inflammatory cytokines [25]. This
is relevant for a disease such as COPD, where both inflam-
mation and tissue damage are present.
Amongst the growth factors induced in TNF-α/IL-1β-
stimulated MSCs, EGFR ligands and HGF are involved
Fig. 5 Blocking of EGFR reduces the stimulatory effect of MSC-CMSTIM on wound closure. a: NCI-H292 wounded cell layers were stimulated with MSC-
CMSTIM or DMEMSTIM, DMEMCTRL, or DMEM supplemented with TGF-α 20 ng/ml or HGF 20 ng/ml (positive controls). Inhibitors of EGFR (0.2 μM
AG1478) or c-Met (0.05 μM PF04217903) were added during the full culture period in assigned conditions. At 48 h, HGF and TGF-α both significantly
enhanced wound healing in NCI-H292 cells, which was averted to a level comparable to the negative control by their respective inhibitors. b: In the
presence of the EGFR inhibitor, the wound healing capacity of MSC-CMSTIM decreased to values below those observed in the negative control as deter-
mined after 48 h. Inhibition of c-Met alone had no effect on wound healing induced by MSC-CMSTIM. Box and whiskers represent median, interquartile
range and minimum and maximum. n = 4-7; (*) p < 0.05
Fig. 6 Proposed model of enhanced wound closure in airway epithelial cells by MSC-CMSTIM. In MSCs, exposure to TNF-α and IL-1β increases the
mRNA expression of various growth factors. Conditioned medium from these MSCs contributes to wound healing of airway epithelial cells via three
mechanisms: direct activation of EGFR; activation of matrix metalloproteases which results in shedding of membrane bound EGFR ligands; induction of
mRNA expression of EGFR ligands by the airway epithelium. Activation of the downstream MAP kinase ERK1/2, which is known as a regulator of cell
proliferation (a.o. assessed by increased Cyclin D1) and differentiation, subsequently results in increased wound healing
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in airway epithelial wound repair [41–44]. By using in-
hibitors for EGFR and c-Met, we show that the effect of
MSC-CMSTIM on both ERK1/2 activation as well as on
wound healing was mediated by EGFR activation, with-
out an apparent effect of c-Met inhibition. As it has
been shown that HGF can promote airway epithelial
wound repair [43, 44], we speculate that in our model
HGF has a more subtle contribution to wound healing
that is masked by the major role of EGFR signaling in
airway epithelial repair. This is supported by a study
from Curley et al., who showed that the addition of
HGF-neutralizing antibodies to MSC-CM in a scratch
wound assay using A549 alveolar epithelial cells did not
affect wound repair [45]. Besides HGF and EGFR li-
gands, other MSC-CMSTIM constituents can contribute
to wound healing. One example of a possibly involved
MSC-derived mediator is IL-6, which was previously
found to contribute to MSC-mediated epithelial wound
repair [36, 46]. Although in our model blocking of EGFR
fully inhibited the stimulatory effect of MSC-CMSTIM,
we cannot exclude a contribution of MSC-derived IL-6.
In addition to direct EGFR activation, we observe that
MSC-CMSTIM activates ERK1/2 via transactivation of
EGFR. EGFR-transactivation results from activation of G-
protein coupled receptors (GPCRs) that activate proteases
of the ADAM family, such as TACE/ADAM17. These
proteases cleave cell surface-bound EGFR ligands, result-
ing in autocrine EGFR activation [34]. Numerous factors
are able to activate GPCRs, and our study focussed on the
role of a modest selection of growth factors and chemo-
kines. It was beyond the scope of this study to investigate
other ligands potentially released by MSCs, but this will
be an interesting point for future investigations.
In our model, we have used the airway epithelial cell
line NCI-H292. This cell line has been shown to respond
in a similar fashion as primary epithelial cells of the lung
and is frequently used to study effects mediated by the
EGFR axis [47–50]. The use of a cell line limits transla-
tion to the in vivo situation, where in addition to the
epithelium also immune and endothelial cells interact in
the process of wound repair. The benefit on the other
hand is that it allows for detailed investigation of MSC-
CMSTIM effects on the ERK1/2 signaling pathway as well
as on cell proliferation.
The circular wounds used in this study are relatively
large and NCI-H292 cells require cell proliferation in
order to close this type of wound as we have shown pre-
viously [32]. This adds information about effects on cell
proliferation that cannot be obtained when using pri-
mary bronchial epithelial cells (PBEC) using wounds of a
similar size, as migratory mechanisms appear to suffice
for the closure of this type of wounds [51]. For the same
reasons, the wound repair model also provides add-
itional information to the more commonly used scratch
wound assays, as these scratch wounds close quickly,
and primarily via cell migratory mechanisms [17]. Using
ALI-PBEC, we observed effects of MSC-CMSTIM on epi-
thelial wound healing, but unlike the observation in
NCI-H292, this effect was not significantly different
compared to control medium (DMEMSTIM). We speculate
that higher intrinsic rate of wound closure in ALI-PBEC
and donor variability limited the experimental window to
observe beneficial effects of MSC-CM. Besides, differences
in intrinsic wound healing characteristics (e.g. primarily
via migration rather than proliferation in ALI-PBEC), as
well as direct effects of TNF-α and IL-1β on migratory
processes might further explain differences in effects of
MSC-CMSTIM on ALI-PBEC versus NCI-H292.
Our data provide evidence for the concept of a cell-based
therapy with cells that specifically interact with an inflam-
matory environment to enhance their beneficial properties.
Safety concerns regarding tumorigenesis or fibrosis might
arise when using cell-based therapies, but based on current
data obtained from clinical trials the use of MSCs in pa-
tients is considered to be safe [52]. Moreover, it has been
shown in multiple studies that MSCs can induce apoptosis
of cancer (but not healthy) cells via tumor necrosis factor-
related apoptosis-inducing ligand [53, 54].
MSCs are currently considered as treatment for COPD
and the first patient safety and feasibility study has re-
cently been published [55]. Interestingly, the results
from the present study suggest that exposure of MSCs
to pro-inflammatory cytokines increases their ability to
repair damaged tissue. This may imply that MSCs are
more effective at sites of inflammation and that in vitro
stimulation of MSCs with cytokines before infusion in
patients may potentially result in a larger therapeutic
effect. Future investigations should be directed at
further exploring the mechanisms involved in the
enhancing effect of MSCs on epithelial wound heal-
ing, using e.g. primary airway and alveolar epithelial
cells, preferably using co-cultures of MSCs with epi-
thelial cells.
Conclusions
We have found that MSC conditioned medium obtained
from MSCs stimulated with a mixture of cytokines po-
tently enhances wound repair in injured airway epithelial
cells. This effect is predominantly mediated by (trans)ac-
tivation of EGFR and subsequent activation of the
ERK1/2 signaling cascade. This observation implies that
in areas of tissue damage where inflammatory mediators
are present (such as in the lungs of COPD patients),
MSCs may display increased regenerative properties via
the secretion of growth factors. This supports the con-
cept that MSCs are a promising candidate for cell-based
therapy in inflammatory lung diseases such as COPD.
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